1. Scrip
  2. >>New Products

Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer

 
• By Sten Stovall

AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage in metastatic breast cancer.

Samples
AZ And Merck Seek Lynparza Use Across Multiple Tumor Settings • Source: Shutterstock

Commercial prospects for the six-month-old global collaboration between AstraZeneca PLC and Merck & Co. Inc. to jointly develop and commercialize AZ's Lynparza (olaparib) got a big boost Jan. 12 when the FDA expanded use of the PARP inhibitor to include treatment of patients with metastatic breast cancer who have a mutated BRCA gene, the first such regulatory approval globally.

The okay was based on data from the randomized, open-label, Phase III OlympiAD trial which found olaparib monotherapy had a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

More from Scrip

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.